Azaya Launches New CDMO - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Azaya Launches New CDMO
Parexo Labs, a division of Azaya, launches as a new CDMO with an emphasis on nanotechnology and liposomal manufacturing.


Azaya Therapeutics, a biopharmaceutical company focused on focused on developing cancer treatments through its nanotechnology platform, announced the launch of a new division, Parexo Labs, as a CDMO providing chemical testing and liposomal manufacturing services to outside organizations. Parexo Labs will offer capabilities in cytotoxic and nanoparticle analysis and liposome manufacturing, including proprietary analytical methodology to detail release rates and characterization attributes of nanoparticles.

“Azaya Therapeutics has over 10 years of experience in the cytotoxic and nanotechnology arenas, which we are now leveraging with the rollout of Parexo Labs,” said Mike Dwyer, Azaya Therapeutics CEO and president, in a company press release. “Through Parexo, we can apply these analytical capabilities and development methodologies to organizations in need of them for their own development programs.”


Parexo Labs services cover method development and validation for cytotoxics, as well as raw material testing, stability storage and testing, chemical characterization and other analyses. Parexo also provides customized liposome manufacturing services, based on its proprietary nanoparticle release methodology.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
35%
Breakthrough designations
12%
Protecting the supply chain
35%
Expedited reviews of drug submissions
12%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges

Click here